Clinical ResearchClinical TrialPrognostic Value of B-Type Natriuretic Peptides in Patients With Stable Coronary Artery Disease: The PEACE Trial
Abbreviations and Acronyms
Cited by (0)
Supported by a contract from the National Heart, Lung, and Blood Institute (N01HC65149) and by Knoll Pharmaceuticals and Abbott Laboratories, which also provided the study medication and kits and financial support for BNP analysis, and by Roche Diagnostics, which provided kits and financial support for N-terminal pro-B-type natriuretic peptide analysis.
Brigham and Women’s Hospital has been awarded patents regarding the use of inhibition of the renin-angiotensin system in selected survivors of myocardial infarction; Drs. Pfeffer and Braunwald are among the coinventors; the licensing agreement with Abbott Laboratories and Novartis is not linked to sales. Mariell L. Jessup, MD, FACC, served as Guest Editor for this article.
See accompanying online Cardiosource Slide Set.
- 1
Drs. Jablonski and Rice are supported in part by NIH/NHLBI grant N01 HC065149 and a supplement from Knoll Pharmaceuticals and Abbott Laboratories.
- 2
Dr. Omland has received speaker’s honoraria from Abbott Laboratories, Bayer Diagnostics, and Roche Diagnostics.
- 3
Dr. Sabatine has received a research grant from Roche Diagnostics.
- 4
Drs. Jablonski and Rice have received research grants from Knoll Pharmaceuticals and Abbott Laboratories.
- 5
Dr. Hsia has received speaker’s honoraria from Abbott Laboratories.
- 6
Dr. Hall is an inventor of 2 patents, owned by Medinnova, Norway, concerning measurement of N-terminal natriuretic peptides.